Ethical Concerns about Psilocybin Intellectual Property
- Konstantin GerberKonstantin GerberPontifical Catholic University of São Paulo, São Paulo, 05014-901, BrazilMore by Konstantin Gerber
- ,
- Inti García FloresInti García FloresArchivo “Historias y Memorias Mazatecas”, Huautla de Jiménez, 68500, MexicoMore by Inti García Flores
- ,
- Angela Christina Ruiz
- ,
- Ismail AliIsmail AliMultidisciplinary Association for Psychedelic Studies, Santa Cruz, California 95060-9989, United StatesMore by Ismail Ali
- ,
- Natalie Lyla GinsbergNatalie Lyla GinsbergMultidisciplinary Association for Psychedelic Studies, Santa Cruz, California 95060-9989, United StatesMore by Natalie Lyla Ginsberg
- , and
- Eduardo E. Schenberg*Eduardo E. Schenberg*Email: [email protected]Instituto Phaneros, São Paulo, 01451-001, BrazilMore by Eduardo E. Schenberg
Abstract

Since a 1957 exposé in Life Magazine, chemical compounds derived from Psilocybe mushrooms have been the focus of dozens of attempted and successful patents, most recently to treat depression. Regrettably, the Mazatec indigenous communities who stewarded these traditional medicines for millenia are not party to any of these patents, despite a number of international treaties asserting indigenous rights to their intangible cultural heritage.
SPECIAL ISSUE
This article is part of the
In 1957, Life magazine published one of the most impactful articles in modern history about psychedelics. “Seeking the magic mushroom” (1) was written by a former J.P. Morgan banker named R. Gordon Wasson. Within two years of the story’s publishing, psilocin and psilocybin, the main active compounds in the mushrooms, were isolated, characterized, synthesized and named by Swiss chemist Albert Hofmann at the Sandoz pharmaceutical company. Sandoz quickly patented the extraction procedure and a method for “therapeutic tranquilization”, marketing pills under the trade name Indocybin. (2)
Six decades later, North-American and European businessmen disproportionately reap financial gain from psychedelics. In October 2020, one of the first pharmaceutical companies focused on developing psilocybin for the treatment of depression went public, and has a current market value of approximately $1.5 billion. (3) According to the World Health Organization, depression affects 264 million people worldwide, (4) and is a leading cause of disability in the 21st century. This constitutes a market which can surpass 200 billion dollars in the USA alone. (5) Therefore, with a neoliberal lens, developments with psilocybin are considered significant advances involving ethnopharmacology, chemistry, psychopharmacology, toxicology, psychology, and psychiatry.
From an indigenous perspective, psilocybin research and drug development tells a story of extraction, cultural appropriation, bioprospecting, and colonization. In Life Magazine’s article, R. Gordon Wasson wrote of his expeditions to Oaxaca, Mexico, seeking the sacred rites and mushrooms of the Mazatec people, and learning from a curandera he initially protected with the pseudonym, Eva Mendez. Eva Mendez guided Wasson on the sacred veladas, in exchange for Wasson’s promise of secrecy, including a promise to never publish photos. However, Wasson ultimately betrayed his promise and revealed his teacher’s identity, curandera Maria Sabina, in his second volume: Mushrooms, Russia and History. He also widely published and publicized her photographs, thus constituting further betrayal. (1) After Wasson’s visit to Huautla de Jimenez, conflict ensued; Maria Sabina was briefly jailed and her house was set on fire. (1) Details of the story vary according to different accounts, (6−9) but these sacred Mazatec rituals were well hidden for centuries. Many indigenous spiritual practices were brutally persecuted and banned during the Spanish inquisition and conquest; thousands were slaughtered. That these rituals survived the events between the inquisition to Wasson’s first visit reveals their strong resilience; for the Mazatec, these mushrooms and traditions are still sacred and the last healing resource as a medicine (Figure 1).
Figure 1

Figure 1. Town of Huautla de Jiménez in Oaxaca and some key cultural elements in the Mazatec mushroom culture. (A) Huautla de Jiménez, Naxín Nanda Tejao. (People of deer, water and eagle). (B) Ndí xijto (little things that sprout, landslides). (C) Ndí xijto (little things that sprout, landslides). (D) Ndí xijto (little things that sprout, landslides). (E) Candles, cacao, and macaw feathers; some elements used in healing Mazatec rituals. (F), (G), and (H) Ndí xijto (little things that sprout, landslides). Photos by Inti Gracía Flores.
Less than a month after Wasson’s article on May 13th, 1957, the Governing Body of the International Labour Office convened in Geneva, on June 5th, 1957, to establish the Indigenous and Tribal Populations Convention No 107. As Mexico adhered on June 01 of 1959, the convention cannot be applied retroactively to the Wasson case. In 1989 this convention was renamed to Indigenous and Tribal Peoples Convention of the International Labour Organization 169. According to its preamble: “in many parts of the world these peoples are unable to enjoy their fundamental human rights to the same degree as the rest of the population of the States within which they live, and that their laws, values, customs and perspectives have often been eroded”. The same convention determined that “the social, cultural, religious and spiritual values and practices of these peoples shall be recognized and protected” (Article 5a) and that “governments shall consult the peoples concerned, through appropriate procedures and in particular through their representative institutions, whenever consideration is being given to legislative or administrative measures which may affect them directly” (Article 6a).
In 1992, 150 world leaders signed the United Nations Convention for Biological Diversity (CBD) in Rio de Janeiro, which directs the signatory States, through national legislation, to “respect, preserve and maintain knowledge, innovations and practices of indigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use of biological diversity and promote their wider application with the approval and involvement of the holders of such knowledge, innovations and practices and encourage the equitable sharing of the benefits arising from the utilization of such knowledge, innovations and practices” (Article 8j). The CBD was followed by other agreements such as the Cartagena Protocol on Biosafety to the Convention on Biological Diversity (2000) and Nagoya Protocol on Access to Genetic Resources (2010).
These developments culminated in the Convention for the Safeguarding of the Intangible Cultural Heritage 2003 of the United Nations Educational, Scientific and Cultural Organization (UNESCO). According to its preamble, it was recognized that “in particular indigenous communities, groups and, in some cases, individuals, play an important role in the production, safeguarding, maintenance and re-creation of the intangible cultural heritage, thus helping to enrich cultural diversity and human creativity”. Intangible cultural heritage was defined as “the practices, representations, expressions, knowledge, skills–as well as the instruments, objects, artefacts and cultural spaces associated therewith–that communities, groups and, in some cases, individuals recognize as part of their cultural heritage” (Article 2.1). In 2007, the United Nations Declaration on the Rights of Indigenous Peoples (UNDRIP) was adopted by a majority of 144 states in favor and 4 votes against which were later reversed, establishing that “indigenous peoples have the right to practise and revitalize their cultural traditions and customs”, including “the right to maintain, protect and develop the past, present and future manifestations of their cultures, such as archaeological and historical sites, artefacts, designs, ceremonies, technologies and visual and performing arts and literature” (Article 11.1) determining that “States shall provide redress through effective mechanisms, which may include restitution, developed in conjunction with indigenous peoples, with respect to their cultural, intellectual, religious and spiritual property taken without their free, prior and informed consent or in violation of their laws, traditions and customs” (Article 11.2).
These advancements imply that traditional knowledge is not an open access unregulated market. (10) Indigenous people have the right to protect, preserve, and develop their traditional practices and medicinal knowledge, and are entitled to benefit from developments based on their intangible cultural heritage, including their spiritual practices. According to these treaties and regulations, bioprospecting must include previous informed consent of the communities involved. Most laws on the matter were developed as a consequence of the CBD, now one of the international treaties with the highest number of signatories in history. However, there are still a series of important issues pending and ongoing debates on how to best achieve just and fair consultations and agreements, respecting ethical, epistemological, and ecological concerns, and how to properly share the benefits in the case of private properties of pharmaceutical corporations based on cumulative collective knowledge of indigenous peoples. (10,11)
Researching psilocybin is configuring a bioprospecting project resulting in the pharmaceutical industry pursuing innovation through intellectual property rights with no plans for reciprocity with or compensation for the indigenous communities who have protected these traditional mushroom practices for millennia. Thus, it is critical to reconsider the neoliberal pharmaceutical approach, including basic science to clinical science, and the implications of its stated goals. In the case of psilocybin, for which there are now at least 24 registered patent processes (Table 1), no pharmaceutical psilocybin developers have reached any legitimate or reciprocal agreements with the Mazatecs, or any other indigenous communities.
owner/assignee | patent/pub. no. | title | priority date (yyyy-mm-dd) | status | general subject matter |
---|---|---|---|---|---|
University of Padova, IRB Barcelona | WO2020181194A1 | compositions and methods of use comprising substances with neural plasticity actions administered at nonpsychedelic/psychotomimetic dosages and formulations | 2019-03-07 | published | microdosing with structural analogues of psilocin, norpsilocin, psilocybin, baeocystin, norbaeocystin, DOI, DMT, LSD, and ibogaine |
Diamond Therapeutics | WO2020157569A1 | methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders | 2019-01-30 | published | treating a neurological condition by administration of a serotonin receptor agonist, including psilocybin |
Apollo Neuroscience | US20200215297A1 | systems and methods of mitigating negative effects of therapies with transcutaneous vibration | 2019-01-04 | pending in US | transcutaneous vibratory simulation during psilocybin-assisted psychotherapy |
Yale University and U.S. Dept. of Veterans Affairs | WO2020041329A1 | combination therapy for treating or preventing depression or other mood diseases | 2018-08-20 | published | treating a mood disorder, by administration of compositions including psilocybin |
Robert Petcavich | WO2019246532A1 | method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases | 2018-06-21 | published | treating neurodegenerative disease by administration of a psychedelic, including psilocybin |
VTT Technical Research Centre of Finland | WO2019180309A1 | heterologous production of psilocybin | 2018-03-19 | published | biosynthetic production of psilocybin from host cell |
Akili Interactive | WO2019161050A1 | cognitive platform including computerized elements coupled with a therapy for mood disorder | 2018-02-18 | published | computer systems for psychedelic-assisted psychotherapy |
CaaMTech | US20190142851A1 | compositions comprising a psilocybin derivative and a cannabinoid | 2017-11-16 | pending in US | purified psilocybin derivatives combined with a cannabinoid |
Eleusis | WO2019079742A8 | methods and systems for enhancing safety of psychedelic drug therapies | 2017-10-19 | published | screening a candidate for treatment with psychedelic agent, including psilocybin |
Compass Pathways | US20200199161A1 | preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | 2017-10-09 | pending in US | oral dosage forms of crystalline psilocybin in the form polymorph A |
Compass Pathways | US10519175B2 | preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use | 2017-10-09 | granted 2019-12-31 (expires 2038-10-09) | treating drug resistant depression with crystalline psilocybin in the form polymorph A |
Eleusis | US20200147038A1 | assessing and treating psychedelic-responsive subjects | 2017-04-20 | pending in US | improving mental or physical well-being by administration of a psychedelic, including psilocybin |
CaaMTech | US20180221396A1 | compositions and methods comprising a psilocybin derivative | 2017-02-09 | pending in US | purified psilocybin derivatives, some together with cannabinoids and terpenes, for treatment of psychological disorders |
Procare Beheer | US10729706B2 | psilocybin and/or psilocin in combination with cannabinoids and/or terpenes | 2017-01-18 | granted 2020-08-04 | treating a psychological disorder by administration of psilocybin together with a cannabinoid and/or a terpene |
Joseph Rustick | US10596378B2 | method for treatment of depression using synaptic pathway training | 2016-10-18 | granted 2020-03-24 (expires 2038-06-07) | treating a neurologic condition by synaptic pathway training, including by administration of psilocybin |
Insectergy LLC | US10738268B2 | cannabis nanoemulsion methods | 2016-08-21 | granted 2020-08-11 (expires 2036-11-01) | cannabis oil nanoemulsions with various compounds including psilocybin |
Paul Stamets | US20190192498A1 | psilocybin compositions | 2016-07-23 | pending in US | compositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to treat neurological or mental health disorders |
Paul Stamets | US20190105313A1 | psilocybin compositions | 2016-07-23 | pending in US | compositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to treat neurological or mental health disorders |
Paul Stamets | US20180021326A1 | compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin | 2016-07-23 | abandoned | compositions of psilocybin, niacin, and mushroom or cannabis extracts, and their use to improve neurological health |
Emory University | US20120108510A1 | methods of improving behavioral therapies | 2010-05-20 | abandoned | psychedelic-assisted psychotherapy |
Galenea Corp | US20120159656A1 | compositions and methods for evaluating cognitive defects | 2009-04-24 | abandoned | using psilocybin to identify a candidate therapeutic agent for treatment of a cognitive deficit |
Koninklijke DSM N.V. (formerly Microbia Inc.) | US7229784B2 | modulation of secondary metabolite production by zinc binuclear cluster proteins | 2000-09-19 | granted 2007-06-12 (expires 2023-06-05) | improving yield of fungal metabolites in bioengineered cells, including psilocybin |
Sandoz | US3192111A | method of inducing therapeutic tranquilization with psilocybin and psilocin | 1959-02-16 | expired | using psilocybin and psilocin to induce tranquilization |
Sandoz | US3183172A | obtaining psilocybin and psilocin from fungal material | 1958-02-21 | expired | extracting psilocybin and psilocin from fungal material |
Source: https://psilocybinalpha.com/data/psilocybin-patent-tracker. (accessed Oct 14th, 2020).
Some important considerations are warranted, especially regarding the many species of mushrooms now identified in the genus Psilocybe and the issue of spirituality. The mushrooms Wasson brought out of Huautla de Jimenez are the basis of the current commodification of psilocybin; they were identified as Psilocybe mexicana, but hundreds of others are now known, some which can even be cultivated indoors. Yet, despite some of these being native and endemic to Europe, for example, Psilocybe semilanceata, reported centuries ago as intoxicating or poisonous, there is little to no evidence of interest in their medical properties in western scientific literature before Wasson’s historical account, thus corroborating the sine qua non role of the Mazatec in all further psilocybin developments. For the Mazatec, the mushrooms are primarily used as medicine, to treat sick people, although in a context and worldview which can be characterized as spiritual by western scholars. And although western science tends to dismiss or disregard spiritual issues in drug development, some of the most important psilocybin studies to date focus exactly on the spirituality domain. Even neuroscientific studies reveal correlations between spiritual or mystical experiences with treatment outcomes in depression. (12)
Developments in psilocybin science and research are intimately intertwined with the Mazatec intangible cultural heritage, raising concerns about harms caused by intellectual property regimes. As the biodiversity regime can be applied to patents in the future, but not retroactively to isolated psilocybin patents obtained by Sandoz Ltd. in 1965, the question is how to protect and develop traditional medicine ceremonies in a way that serves indigenous communities? Why is the so-called psychedelic renaissance, including commodification, almost exclusively benefiting nonindigenous Western businessmen? Is there any restitution or reparation to be done in this case?
Raids and extractive activities continue to this day in the Mazatec land. Mycologists, biologists, speleologists, and scientists descend upon the Mazatec community, without asking for permission from or adequately explaining their research to the community. Some researchers claim they received permission and have protocols to specifically work with the indigenous communities, but it is not clear what kind of permission was requested or from whom it was received. Instead, a Mazatec communitary protocol could be developed in order to consent with the researchers on the biocultural heritage. The racialized and colonial western mindset contributes to Westerners’ ongoing delegitimization of indigenous community-held knowledge. Westerners consciously or subconsciously racialize and demean the Mazatec as the “noble savage.” Western scientists and researchers tell Mazatec chojta chijne (wisdom bearers) that they in fact are naming the mushrooms incorrectly, and that they do not know the range of their local mushrooms.
Depression is considered a disorder based in a series of social determinants, many of which can be dramatically exacerbated by colonial and extractive enterprises. Notably, studies about depression cite causes including grief, loss of significant personal relationships in communities, loneliness, stress and past history of abuse, physically, mentally, and emotionally. Bioprospecting and biopiracy often cause conflicts, tensions, disconnection, poverty, and suffering in the communities from which the knowledge and tradition originate. This suffering tracks onto our understanding of how one’s social and cultural environment can affect mental health. In other words, nonconsensual extractive for-profit ventures based on intellectual property regimes can cause intergenerational distress and suffering in impacted indigenous communities in a way that could actively perpetuate mental illness, while cutting them off from rightful benefits derived from their intangible cultural heritages. As depression both perpetuates and emerges from socio-economic barriers, so the idea of its treatment being extracted from highly traumatized populations to benefit the current healthcare economy indicates an ethical oversight on the part of most western scientists and researchers. The motivations behind a highly profitable business selling psilocybin as a panacea for this century forces us to ask: will this treatment really be affordable to all social stratum, or only for a privileged part of society?
Aiming for justice, the Mazatec must benefit for their centuries-long stewardship of these sacred rituals and knowledge. Since these Mazatec rituals became public in 1957, no one has sought reparation or reciprocity with the communities in a fair manner. This implies extraction in all aspects and meanings, including abuse of the Mazatec people’s hospitality.
As the third decade of the 21st century unfolds, the survival of indigenous peoples and our natural world is gravely threatened at an unprecedented level by construction, mining, logging, and energy “development programs” for the benefit of shareholder driven corporations. When the intellectual “property” derived from naturally occurring compounds is the prior art of indigenous people, we are obliged to explore the ethics of shareholders reaping the financial benefit from these compounds. Reflecting on these ethical dilemmas may offer frameworks to understand and solve for the ongoing harm of extractive economics, and perhaps even point the way toward reciprocal and reparative arrangements with indigenous stewards of medicines and molecules around the world.
Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.0c00171.
This article in the Mazatec language (DOCX)
Terms & Conditions
Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.
References
This article references 12 other publications.
- 1Siff, S. (2018) R. Gordon Wasson and the Publicity Campaign to Introduce Magic Mushrooms to Mid-Century America. Revue française d’études américaines 156 (3), 91– 104, DOI: 10.3917/rfea.156.0091Google ScholarThere is no corresponding record for this reference.
- 2Dieter Hagenbach and Lucius Werthmüller (2011). Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD, Synergetic Press, Santa Fe, NM.Google ScholarThere is no corresponding record for this reference.
- 3Wooley, S. (2020). ‘ Magic Mushroom’ Company Goes Mainstream, Jumps 71% Post-IPO. Bloomberg, https://www.bloomberg.com/news/articles/2020-09-18/-magic-mushroom-company-moves-toward-mainstream-in-nasdaq-ipo (accessed 2020-10-14).Google ScholarThere is no corresponding record for this reference.
- 4James, S. L, Abate, D., Abate, K. H. (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study. Lancet 392 (10159), 1789– 1858, DOI: 10.1016/S0140-6736(18)32279-7Google ScholarThere is no corresponding record for this reference.
- 5Gauthier, G., Mucha, L., Shi, S., and Guerin, A. (2019) Economic burden of relapse/recurrence in patients with major depressive disorder. Journal of drug assessment 8 (1), 97– 103, DOI: 10.1080/21556660.2019.1612410Google Scholar5https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mtVGnug%253D%253D&md5=b9f8c4949740966c35800669c3171759Economic burden of relapse/recurrence in patients with major depressive disorderGauthier Genevieve; Shi Sherry; Guerin Annie; Mucha LisaJournal of drug assessment (2019), 8 (1), 97-103 ISSN:2155-6660.Objective: This study was conducted to determine the incremental healthcare resource utilization (HRU) and costs associated with relapse or recurrence (R/R) in patients with major depressive disorder (MDD) treated with antidepressants (AD) in US clinical practice. Methods: In this retrospective cohort study, adult patients with MDD treated with a branded AD were selected from the Truven Health Analytics MarketScan Databases (January 1, 2004-March 31, 2015). Time to first indicator of R/R was described. Characteristics, HRU, and costs were compared between patients with and without R/R. Among patients with R/R, HRU and costs were also compared between the pre- and post-R/R period. Results: From the 22,236 selected patients, 5,541 had ≥ 1 indicator of R/R and 16,695 did not. The 3-year R/R rate varied between 21.3% and 36.4% based on pattern of AD use (continuous, switch/augmentation, or early discontinuation). Patients with and without R/R presented different characteristics-notably, more intensive prior AD use and a higher comorbidity burden. HRU and costs were high in both patients with and without R/R but substantially higher among those with R/R ($20,590 vs $12,368 per-patient-per-year (PPPY); adjusted difference [aDiff] = $7,037), mainly driven by increased inpatient (IP) services (adjusted incidence rate ratio IP days = 3.95; aDiff IP costs = $3,433 PPPY). Among patients with R/R, emergency department visits, IP days, and IP admissions were over 2-times higher during the post-R/R period and total costs increased by over 50% from $19,267 to $29,419 in the post-R/R period. Conclusions: The economic burden in MDD patients is substantial, but is significantly higher among those who experience R/R.
- 6Estrada, Á. (1976) Vida de María Sabina: la sabia de los hongos, ISBN 968-23-0513-6.Google ScholarThere is no corresponding record for this reference.
- 7Feinberg, B. (2003) The Devil’s Book of Culture: History, Mushrooms, and Caves in Southern Mexico, ISBN 0-292-70190-X.Google ScholarThere is no corresponding record for this reference.
- 8Gonzáles, E. (1992) Conversaciones con María Sabina y Otros Curanderos, ISBN 2575-9108 (in Spanish).Google ScholarThere is no corresponding record for this reference.
- 9Rothenberg, J. Ed. (2003) María Sabina: Selections, ISBN 0-520-23953-9.Google ScholarThere is no corresponding record for this reference.
- 10Shiva, V. (2020) Reclaiming the Commons: Biodiversity, Traditional Knowledge, and the Rights of Mother Earth, Synergetic Press, Santa Fe, NM.Google ScholarThere is no corresponding record for this reference.
- 11McGonigle, I. V. (2016) Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights. Journal of Law and the Biosciences 3 (1), 217– 226, DOI: 10.1093/jlb/lsw003Google Scholar11https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srlsVOjtQ%253D%253D&md5=06f86317dad6d1ee30dd0ad09871c4d6Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rightsMcGonigle Ian VincentJournal of law and the biosciences (2016), 3 (1), 217-226 ISSN:2053-9711.Ethnopharmacologists are scientists and anthropologists that study indigenous medicines and healing practices, and who often develop new therapies and medicines for wider use. Ethnopharmacologists do fieldwork with indigenous peoples in traditional societies, where they encounter a wide range of cultural values and varying ideas about the nature of property relations. This poses difficulties for protecting indigenous intellectual property and for making just trade agreements. This Note reviews the legal issues relevant to the protection of indigenous resources in ethnopharmacology trade agreements, and suggests that recent developments in anthropology and the social study of science could be instructive in furthering the legal discourse and in providing policy directions. Specifically, the Note introduces the concepts of 'ontological pluralism' and 'epistemic subsidiarity', which could help lawmakers write sui generis trade agreements to better protect indigenous knowledge and resources.
- 12Roseman, L., Nutt, D. J., and Carhart-Harris, R. (2018) Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol. 8, 1– 10, DOI: 10.3389/fphar.2017.00974Google ScholarThere is no corresponding record for this reference.
Cited By
This article is cited by 21 publications.
- David E. Olson. The Promise of Psychedelic Science. ACS Pharmacology & Translational Science 2021, 4
(2)
, 413-415. https://doi.org/10.1021/acsptsci.1c00071
- Patricia Kubala. Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’. Deleuze and Guattari Studies 2023, 17
(4)
, 482-505. https://doi.org/10.3366/dlgs.2023.0531
- Henry Harder, Fabian Pitter Steinmetz, Maja Kohek. The Psychedelic Social Club: a regulatory concept for people who use psychedelics?. Drugs: Education, Prevention and Policy 2023, 19 , 1-11. https://doi.org/10.1080/09687637.2023.2276067
- Nuno Azevedo, Miguel Oliveira Da Silva, Luís Madeira. Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges. Philosophies 2023, 8
(5)
, 76. https://doi.org/10.3390/philosophies8050076
- Dominique Strauss, Soumya Ghosh, Zurika Murray, Marieka Gryzenhout. Global species diversity and distribution of the psychedelic fungal genus Panaeolus. Heliyon 2023, 9
(6)
, e16338. https://doi.org/10.1016/j.heliyon.2023.e16338
- Meg J. Spriggs, Ashleigh Murphy-Beiner, Roberta Murphy, Julia Bornemann, Hannah Thurgur, Anne K. Schlag. ARC: a framework for access, reciprocity and conduct in psychedelic therapies. Frontiers in Psychology 2023, 14 https://doi.org/10.3389/fpsyg.2023.1119115
- Osiris González Romero. Cognitive liberty and the psychedelic humanities. Frontiers in Psychology 2023, 14 https://doi.org/10.3389/fpsyg.2023.1128996
- Dominique Strauss, Soumya Ghosh, Zurika Murray, Marieka Gryzenhout. Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. 3 Biotech 2022, 12
(12)
https://doi.org/10.1007/s13205-022-03355-4
- Sean J. Belouin, Lynnette A. Averill, Jack E. Henningfield, Stephen N. Xenakis, Ingrid Donato, Charles S. Grob, Ann Berger, Veronica Magar, Alicia L. Danforth, Brian T. Anderson. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology 2022, 219 , 109214. https://doi.org/10.1016/j.neuropharm.2022.109214
- Eduardo Ekman Schenberg, Konstantin Gerber. Overcoming epistemic injustices in the biomedical study of ayahuasca: Towards ethical and sustainable regulation. Transcultural Psychiatry 2022, 59
(5)
, 610-624. https://doi.org/10.1177/13634615211062962
- Ayse Ceren Kaypak, Amir Raz. Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives. Transcultural Psychiatry 2022, 59
(5)
, 665-674. https://doi.org/10.1177/13634615221119386
- Christine Hauskeller, Taline Artinian, Amelia Fiske, Ernesto Schwarz Marin, Osiris Sinuhé González Romero, Luis Eduardo Luna, Joseph Crickmore, Peter Sjöstedt-Hughes. Decolonization is a metaphor towards a different ethic. The case from psychedelic studies. Interdisciplinary Science Reviews 2022, 9 , 1-20. https://doi.org/10.1080/03080188.2022.2122788
- Keith Williams, Osiris Sinuhé González Romero, Michelle Braunstein, Suzanne Brant. Indigenous Philosophies and the "Psychedelic Renaissance". Anthropology of Consciousness 2022, 33
(2)
, 506-527. https://doi.org/10.1111/anoc.12161
- Jesús M. González‐Mariscal, Paulina E. Sosa‐Cortés. Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine. Anthropology of Consciousness 2022, 33
(2)
, 358-384. https://doi.org/10.1111/anoc.12168
- Snehal R. Bhatt, Maya Armstrong, Tassy Parker, Marcello Maviglia, Rebecca Kass, Lawrence Leeman, Paul Romo, Douglas Ziedonis. Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Frontiers in Pharmacology 2022, 13 https://doi.org/10.3389/fphar.2022.905753
- R.C. Van Court, M.S. Wiseman, K.W. Meyer, D.J. Ballhorn, K.R. Amses, J.C. Slot, B.T.M. Dentinger, R. Garibay-Orijel, J.K. Uehling. Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biology 2022, 126
(4)
, 308-319. https://doi.org/10.1016/j.funbio.2022.01.003
- Roberta Murphy, Hannes Kettner, Rick Zeifman, Bruna Giribaldi, Laura Kartner, Jonny Martell, Tim Read, Ashleigh Murphy-Beiner, Michelle Baker-Jones, David Nutt, David Erritzoe, Rosalind Watts, Robin Carhart-Harris. Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Frontiers in Pharmacology 2022, 12 https://doi.org/10.3389/fphar.2021.788155
- Ilana Berlowitz, David M. O'Shaughnessy, Michael Heinrich, Ursula Wolf, Caroline Maake, Chantal Martin-Soelch. Teacher plants — Indigenous Peruvian-Amazonian dietary practices as a method for using psychoactives. Journal of Ethnopharmacology 2022, 286 , 114910. https://doi.org/10.1016/j.jep.2021.114910
- IIana Berlowitz. Plantes psychotropes, médecines traditionnelles autochtones du Pérou et renaissance
psychédélique. Drogues, santé et société 2022, 20
(1)
, 90-116. https://doi.org/10.7202/1090700ar
- Martin L. Williams, Diana Korevaar, Renee Harvey, Paul B. Fitzgerald, Paul Liknaitzky, Sean O'Carroll, Prashanth Puspanathan, Margaret Ross, Nigel Strauss, James Bennett-Levy. Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead. Frontiers in Psychiatry 2021, 12 https://doi.org/10.3389/fpsyt.2021.737738
- Riccardo Miceli McMillan. Global bioethical challenges of medicalising psychedelics. Journal of Psychedelic Studies 2021, 5
(2)
, 57-64. https://doi.org/10.1556/2054.2021.00188
Abstract
Figure 1
Figure 1. Town of Huautla de Jiménez in Oaxaca and some key cultural elements in the Mazatec mushroom culture. (A) Huautla de Jiménez, Naxín Nanda Tejao. (People of deer, water and eagle). (B) Ndí xijto (little things that sprout, landslides). (C) Ndí xijto (little things that sprout, landslides). (D) Ndí xijto (little things that sprout, landslides). (E) Candles, cacao, and macaw feathers; some elements used in healing Mazatec rituals. (F), (G), and (H) Ndí xijto (little things that sprout, landslides). Photos by Inti Gracía Flores.
References
ARTICLE SECTIONSThis article references 12 other publications.
- 1Siff, S. (2018) R. Gordon Wasson and the Publicity Campaign to Introduce Magic Mushrooms to Mid-Century America. Revue française d’études américaines 156 (3), 91– 104, DOI: 10.3917/rfea.156.0091Google ScholarThere is no corresponding record for this reference.
- 2Dieter Hagenbach and Lucius Werthmüller (2011). Mystic Chemist: The Life of Albert Hofmann and His Discovery of LSD, Synergetic Press, Santa Fe, NM.Google ScholarThere is no corresponding record for this reference.
- 3Wooley, S. (2020). ‘ Magic Mushroom’ Company Goes Mainstream, Jumps 71% Post-IPO. Bloomberg, https://www.bloomberg.com/news/articles/2020-09-18/-magic-mushroom-company-moves-toward-mainstream-in-nasdaq-ipo (accessed 2020-10-14).Google ScholarThere is no corresponding record for this reference.
- 4James, S. L, Abate, D., Abate, K. H. (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study. Lancet 392 (10159), 1789– 1858, DOI: 10.1016/S0140-6736(18)32279-7Google ScholarThere is no corresponding record for this reference.
- 5Gauthier, G., Mucha, L., Shi, S., and Guerin, A. (2019) Economic burden of relapse/recurrence in patients with major depressive disorder. Journal of drug assessment 8 (1), 97– 103, DOI: 10.1080/21556660.2019.1612410Google Scholar5https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3mtVGnug%253D%253D&md5=b9f8c4949740966c35800669c3171759Economic burden of relapse/recurrence in patients with major depressive disorderGauthier Genevieve; Shi Sherry; Guerin Annie; Mucha LisaJournal of drug assessment (2019), 8 (1), 97-103 ISSN:2155-6660.Objective: This study was conducted to determine the incremental healthcare resource utilization (HRU) and costs associated with relapse or recurrence (R/R) in patients with major depressive disorder (MDD) treated with antidepressants (AD) in US clinical practice. Methods: In this retrospective cohort study, adult patients with MDD treated with a branded AD were selected from the Truven Health Analytics MarketScan Databases (January 1, 2004-March 31, 2015). Time to first indicator of R/R was described. Characteristics, HRU, and costs were compared between patients with and without R/R. Among patients with R/R, HRU and costs were also compared between the pre- and post-R/R period. Results: From the 22,236 selected patients, 5,541 had ≥ 1 indicator of R/R and 16,695 did not. The 3-year R/R rate varied between 21.3% and 36.4% based on pattern of AD use (continuous, switch/augmentation, or early discontinuation). Patients with and without R/R presented different characteristics-notably, more intensive prior AD use and a higher comorbidity burden. HRU and costs were high in both patients with and without R/R but substantially higher among those with R/R ($20,590 vs $12,368 per-patient-per-year (PPPY); adjusted difference [aDiff] = $7,037), mainly driven by increased inpatient (IP) services (adjusted incidence rate ratio IP days = 3.95; aDiff IP costs = $3,433 PPPY). Among patients with R/R, emergency department visits, IP days, and IP admissions were over 2-times higher during the post-R/R period and total costs increased by over 50% from $19,267 to $29,419 in the post-R/R period. Conclusions: The economic burden in MDD patients is substantial, but is significantly higher among those who experience R/R.
- 6Estrada, Á. (1976) Vida de María Sabina: la sabia de los hongos, ISBN 968-23-0513-6.Google ScholarThere is no corresponding record for this reference.
- 7Feinberg, B. (2003) The Devil’s Book of Culture: History, Mushrooms, and Caves in Southern Mexico, ISBN 0-292-70190-X.Google ScholarThere is no corresponding record for this reference.
- 8Gonzáles, E. (1992) Conversaciones con María Sabina y Otros Curanderos, ISBN 2575-9108 (in Spanish).Google ScholarThere is no corresponding record for this reference.
- 9Rothenberg, J. Ed. (2003) María Sabina: Selections, ISBN 0-520-23953-9.Google ScholarThere is no corresponding record for this reference.
- 10Shiva, V. (2020) Reclaiming the Commons: Biodiversity, Traditional Knowledge, and the Rights of Mother Earth, Synergetic Press, Santa Fe, NM.Google ScholarThere is no corresponding record for this reference.
- 11McGonigle, I. V. (2016) Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights. Journal of Law and the Biosciences 3 (1), 217– 226, DOI: 10.1093/jlb/lsw003Google Scholar11https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2srlsVOjtQ%253D%253D&md5=06f86317dad6d1ee30dd0ad09871c4d6Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rightsMcGonigle Ian VincentJournal of law and the biosciences (2016), 3 (1), 217-226 ISSN:2053-9711.Ethnopharmacologists are scientists and anthropologists that study indigenous medicines and healing practices, and who often develop new therapies and medicines for wider use. Ethnopharmacologists do fieldwork with indigenous peoples in traditional societies, where they encounter a wide range of cultural values and varying ideas about the nature of property relations. This poses difficulties for protecting indigenous intellectual property and for making just trade agreements. This Note reviews the legal issues relevant to the protection of indigenous resources in ethnopharmacology trade agreements, and suggests that recent developments in anthropology and the social study of science could be instructive in furthering the legal discourse and in providing policy directions. Specifically, the Note introduces the concepts of 'ontological pluralism' and 'epistemic subsidiarity', which could help lawmakers write sui generis trade agreements to better protect indigenous knowledge and resources.
- 12Roseman, L., Nutt, D. J., and Carhart-Harris, R. (2018) Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol. 8, 1– 10, DOI: 10.3389/fphar.2017.00974Google ScholarThere is no corresponding record for this reference.
Supporting Information
Supporting Information
ARTICLE SECTIONSThe Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.0c00171.
This article in the Mazatec language (DOCX)
Terms & Conditions
Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.